BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29453511)

  • 1. Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer.
    Gilbert R; Tilling K; Martin RM; Lane JA; Davis M; Hamdy FC; Neal DE; Donovan JL; Metcalfe C
    Cancer Causes Control; 2018 Mar; 29(3):383-388. PubMed ID: 29453511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
    Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
    BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.
    Gilbert R; Martin RM; Evans DM; Tilling K; Davey Smith G; Kemp JP; Lane JA; Hamdy FC; Neal DE; Donovan JL; Metcalfe C
    PLoS One; 2015; 10(10):e0136735. PubMed ID: 26431041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
    Partin AW; Criley SR; Subong EN; Zincke H; Walsh PC; Oesterling JE
    J Urol; 1996 Apr; 155(4):1336-9. PubMed ID: 8632568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age specific prostate specific antigen reference ranges: population specific.
    Borer JG; Sherman J; Solomon MC; Plawker MW; Macchia RJ
    J Urol; 1998 Feb; 159(2):444-8. PubMed ID: 9649260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL.
    Fowler JE; Bigler SA; Farabaugh PB
    Cancer; 2002 Mar; 94(6):1661-7. PubMed ID: 11920526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowering the PSA threshold for prostate biopsy from 4 to 2.5 ng/ml: influence on cancer characteristics and number of men needed to biopt.
    Müntener M; Kunz U; Eichler K; Puhan M; Schmid DM; Sulser T; Strebel RT
    Urol Int; 2010; 84(2):141-6. PubMed ID: 20215816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical usefulness of prostate-specific antigen (PSA) level and age-specific PSA reference ranges for detecting prostate cancer in Chinese.
    Wu TT; Huang JK
    Urol Int; 2004; 72(3):208-11. PubMed ID: 15084763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
    Gulati R; Gore JL; Etzioni R
    Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
    Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
    JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.
    Grossfeld GD; Latini DM; Lubeck DP; Mehta SS; Carroll PR
    J Urol; 2003 Jan; 169(1):157-63. PubMed ID: 12478126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
    Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
    BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
    Caster JM; Falchook AD; Hendrix LH; Chen RC
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
    Welch HG; Schwartz LM; Woloshin S
    J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
    Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
    JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.